NCT02332707 - Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) | Biotech Hunter

Enrollment

443

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

September 16, 2016

Study Completion Date

December 6, 2016

Conditions

Hepatitis C

Interventions

DRUG

Grazoprevir

One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

DRUG

Uprifosbuvir

Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

DRUG

Elbasvir

One EBR 50 mg tablet (Part A), taken q.d. by mouth.

DRUG

Ruzasvir

Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

DRUG

Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.

DRUG

Ribavirin

RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY